Related CAS #
56973-26-3 (free base)
66934-73-4 (HCl)
1131657-91-4 (tosylate)
1131657-83-4 (besylate)
1131657-85-6 (mesylate)
1428902-56-0 (hydrate)
66934-72-3 (sodium)
86011-08-7 (HBr)
1428902-57-1 (HCl hydrate)
Synonym
FF-10501; FF 10501; FF10501.
IUPAC/Chemical Name
un5-hydroxy-1H-imidazole-4-carboxamide
InChi Key
UEWSIIBPZOBMBL-UHFFFAOYSA-N
InChi Code
InChI=1S/C4H5N3O2/c5-3(8)2-4(9)7-1-6-2/h1,9H,(H2,5,8)(H,6,7)
SMILES Code
O=C(N)C1=C(O)NC=N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Structure was from Cancers 2019, 11, 1346
Biological target:
FF-1050 is an IMPDH Inhibitor.
In vitro activity:
An in vitro study was conducted to elucidate the mechanisms of FF-10501-induced cell death using 12 hematological malignant cell lines derived from myeloid and lymphoid malignancies. FF-10501 suppressed the growth of each cell line in a dose-dependent manner. However, the clinically relevant dose (40 μM) of FF-10501 induced cell death in three cell lines (MOLM-13, OCI-AML3, and MOLT-3). Investigation of the cell death mechanism suggested that FF-10501 induces both apoptotic and necrotic cell death. FF-10501-induced apoptosis was mediated by caspase-8 activation followed by activation of the mitochondrial pathway in MOLM-13 and MOLT-3 cells. FF-10501 induced necrotic cell death via endoplasmic reticulum stress in OCI-AML3 cells.
Reference: Int J Hematol. 2019 Nov;110(5):606-617. https://dx.doi.org/10.1007/s12185-019-02722-x
Preparing Stock Solutions
The following data is based on the
product
molecular weight
127.10
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
In vitro protocol:
1. Matsumoto T, Jimi S, Migita K, Terada K, Mori M, Takamatsu Y, Suzumiya J, Hara S. FF-10501 induces caspase-8-mediated apoptotic and endoplasmic reticulum stress-mediated necrotic cell death in hematological malignant cells. Int J Hematol. 2019 Nov;110(5):606-617. doi: 10.1007/s12185-019-02722-x. Epub 2019 Aug 12. PMID: 31407254.
1: Matsumoto T, Jimi S, Migita K, Terada K, Mori M, Takamatsu Y, Suzumiya J, Hara
S. FF-10501 induces caspase-8-mediated apoptotic and endoplasmic reticulum
stress-mediated necrotic cell death in hematological malignant cells. Int J
Hematol. 2019 Nov;110(5):606-617. doi: 10.1007/s12185-019-02722-x. Epub 2019 Aug
12. PubMed PMID: 31407254.
2: Ichii M, Oritani K, Murase M, Komatsu K, Yamazaki M, Kyoden R, Kito N, Nozaki
Y, Saito M, Iwamura H, Kanakura Y. Molecular targeting of
inosine-5'-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via
ROS/MAPK pathway. Leuk Lymphoma. 2018 Feb;59(2):448-459. doi:
10.1080/10428194.2017.1339878. Epub 2017 Jul 21. PubMed PMID: 28730859.
3: Murase M, Iwamura H, Komatsu K, Saito M, Maekawa T, Nakamura T, Yokokawa T,
Shimada Y. Lack of cross-resistance to FF-10501, an inhibitor of
inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines
selected from SKM-1 and MOLM-13 leukemia cell lines. Pharmacol Res Perspect. 2016
Jan 28;4(1):e00206. doi: 10.1002/prp2.206. eCollection 2016 Feb. PubMed PMID:
26977297; PubMed Central PMCID: PMC4777262.
